Stratec (SBS) Aktievy
Stratec SE, tillsammans med sina dotterbolag, utvecklar och tillverkar automations- och instrumentlösningar inom områdena in vitro-diagnostik och biovetenskap i Tyskland, EU och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 4/6 |
| Framtida tillväxt | 4/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 2/6 |
SBS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Stratec SE Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | €17.24 |
| 52 veckors högsta | €33.10 |
| 52 veckors lägsta | €16.34 |
| Beta | 0.79 |
| 1 månads förändring | -9.26% |
| 3 månaders förändring | -15.49% |
| 1 års förändring | -34.57% |
| 3 års förändring | -69.75% |
| 5 års förändring | -85.54% |
| Förändring sedan börsintroduktionen | 231.35% |
Senaste nyheter och uppdateringar
Recent updates
Uppdatering av berättelse • May 08
SBS: Lower Growth Assumptions Will Still Allow Future Upside Potential
The analyst fair value estimate for Stratec has been revised from about €26.00 to about €20.00, as analysts trim price targets and factor in lower revenue growth assumptions, softer profit margin expectations, and a higher implied future P/E, in line with recent target cuts from major banks. Analyst Commentary Recent Street research reflects a more cautious stance on Stratec, with price targets revised lower and expectations reset around revenue growth and profitability.
Uppdatering av berättelse • Apr 21
SBS: Rebased Fair Value And 2025 Margin Guidance Will Define Upside Potential
The analyst price target for Stratec has been cut from about €44.96 to €34.00, as analysts factor in updated fair value, discount rate, growth, margin, and P/E assumptions following recent target revisions from major banks. Analyst Commentary Recent research suggests that while headline price targets for Stratec have come down, some bullish analysts still see potential upside at current levels.
Uppdatering av berättelse • Apr 06
SBS: Future Upside Will Rely On Reset Margins And Higher P/E
Narrative Update on Stratec The updated analyst price target for Stratec is €28.46, reflecting recent target cuts of up to €12 from prior Street research as analysts factor in a slightly higher discount rate, modestly adjusted profit margin assumptions, and a higher future P/E multiple. Analyst Commentary Recent research commentary on Stratec has focused on recalibrating price targets while keeping an eye on execution risk and the valuation investors are being asked to pay.Uppdatering av berättelse • Mar 23
SBS: Future Upside Will Depend On Repriced Earnings Power And Margins
Analysts have trimmed their average price target for Stratec by around €2.40, with recent cuts to €34 helping to explain a slightly lower fair value estimate and modestly softer assumptions for growth, margins and future P/E. Analyst Commentary Recent research revisions on Stratec point to a reset in expectations, with lower price targets feeding into updated views on valuation, execution risk and growth assumptions.Uppdatering av berättelse • Mar 09
SBS: Higher Discount Rate And Index Removal Will Still Allow Future Upside
Narrative Update on Stratec The analyst price target for Stratec has been reduced by €1, as analysts reflect slightly adjusted assumptions around discount rates, revenue growth and profit margins in their updated models. Analyst Commentary Bearish analysts trimming their price targets, including the recent €1 reduction, are signaling a more cautious stance on Stratec.Uppdatering av berättelse • Feb 22
SBS: Higher Discount Rate Will Still Allow Future Upside Potential
Analysts have reduced their price target on Stratec by €1 to €26, reflecting updated assumptions regarding the company’s discount rate, revenue growth, profit margin and future P/E profile. Analyst Commentary Bearish analysts cutting the price target to €26 are signaling a more cautious stance on Stratec’s risk and reward trade off at current levels.Uppdatering av berättelse • Feb 08
SBS: Future Upside Will Rely On Earnings Power And Cost Controls
Narrative update on Stratec Analysts have trimmed their 12 month price target on Stratec by about €1, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Recent research updates on Stratec point to a small pullback in published price targets, with a reduction of about €1 in the latest move and a prior cut from €30 to €27.Uppdatering av berättelse • Jan 23
SBS: Future Margin Recovery Will Rely On Efficiency Gains And Cost Controls
Analysts have trimmed their price target on Stratec, with the average moving slightly lower in line with a recent cut from €30 to €27, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Recent research points to a more cautious stance on Stratec, with the reduced €27 price target reflecting updated views on what analysts see as fair value, the applied discount rate, revenue growth assumptions, margin profile and future P/E expectations.Analysartikel • Jan 10
Returns On Capital Signal Tricky Times Ahead For Stratec (ETR:SBS)
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...Uppdatering av berättelse • Jan 08
SBS: Index Exit And 2025 Margin Guidance Will Define Upside Potential
Analysts have trimmed their fair value estimate for Stratec from about €51.00 to roughly €44.96. This aligns with a recent reduction in the Street price target to €27 from €30 as they factor in updated assumptions on discount rates, revenue growth, profit margins, and future P/E multiples.Uppdatering av berättelse • Dec 18
SBS: Margin Recovery Outlook Will Support Upside Despite Reduced Price Objective
Analysts have trimmed their price target on Stratec to EUR 27.00 from EUR 30.00, reflecting slightly more cautious assumptions on long term growth, a higher discount rate, and a modestly lower future P E multiple, despite marginally improved margin expectations. Analyst Commentary Bearish analysts have highlighted that the reduction in the price target to EUR 27.00 signals a more guarded stance on Stratec's medium to long term prospects, even as the rating on the shares remains unchanged at Hold.Uppdatering av berättelse • Dec 04
SBS: Future Margin Gains Will Emerge As Cost Controls Take Hold
Analysts have modestly reduced their price target on Stratec, trimming it by EUR 3 to EUR 27. This reflects slightly lower long term return expectations while maintaining a cautious stance on the shares.Analysartikel • Nov 29
Stratec (ETR:SBS) Takes On Some Risk With Its Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Uppdatering av berättelse • Nov 20
SBS: Margins Will Improve With Cost Management And Leadership Changes
The analyst price target for Stratec has been revised downward from €30 to €27. Analysts cited a slightly higher discount rate and modest changes in growth and profitability expectations as key drivers behind the adjustment.Analysartikel • Nov 11
Stratec SE (ETR:SBS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Stratec SE ( ETR:SBS ) shareholders are probably feeling a little disappointed, since its shares fell 5.2% to €21.75 in...Analysartikel • Nov 07
Investors Give Stratec SE (ETR:SBS) Shares A 35% Hiding
Stratec SE ( ETR:SBS ) shares have had a horrible month, losing 35% after a relatively good period beforehand. The drop...Uppdatering av berättelse • Nov 03
SBS: Future Leadership Will Drive Healthcare Diagnostics Forward Amidst Margin Pressures
Analysts have revised their price target for Stratec downward from €36.58 to €33.30, citing expectations of slower revenue growth and a slight decrease in profit margins. What's in the News Tanja Bücherl will join STRATEC SE's Board of Management as Chief Financial Officer effective November 1, 2025.Analysartikel • Sep 23
Getting In Cheap On Stratec SE (ETR:SBS) Might Be Difficult
Stratec SE's ( ETR:SBS ) price-to-earnings (or "P/E") ratio of 25.3x might make it look like a sell right now compared...Uppdatering av berättelse • Aug 23
Automation And Digitalization Will Transform Healthcare Diagnostics
Stratec’s consensus price target has been revised downward, primarily reflecting lowered forecasts for both revenue growth and net profit margin, resulting in a new fair value of €37.32. What's in the News Stratec increased its dividend to €0.60 per share for 2024 (previously €0.55), totaling €7.3 million to be distributed.Analysartikel • Jun 17
An Intrinsic Calculation For Stratec SE (ETR:SBS) Suggests It's 34% Undervalued
Key Insights Stratec's estimated fair value is €36.05 based on 2 Stage Free Cash Flow to Equity Stratec is estimated to...Analysartikel • Apr 25
Why We're Not Concerned About Stratec SE's (ETR:SBS) Share Price
With a price-to-earnings (or "P/E") ratio of 30.8x Stratec SE ( ETR:SBS ) may be sending very bearish signals at the...
Ny berättelse • Feb 09
Efficiency Measures And Acquisitions Like Natech Will Boost Future Market Presence
Efficiency measures and cost discipline initiatives could enhance net margins as market conditions stabilize.Analysartikel • Jan 18
An Intrinsic Calculation For Stratec SE (ETR:SBS) Suggests It's 42% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Stratec fair value estimate is €55.10 Stratec's €32.10 share...Analysartikel • Nov 09
With A 25% Price Drop For Stratec SE (ETR:SBS) You'll Still Get What You Pay For
Stratec SE ( ETR:SBS ) shares have had a horrible month, losing 25% after a relatively good period beforehand. The drop...Analysartikel • Oct 26
Returns At Stratec (ETR:SBS) Appear To Be Weighed Down
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Analysartikel • May 11
Here's Why It's Unlikely That Stratec SE's (ETR:SBS) CEO Will See A Pay Rise This Year
Key Insights Stratec to hold its Annual General Meeting on 17th of May Total pay for CEO Marcus Wolfinger includes...Analysartikel • Apr 11
Stratec's (ETR:SBS) Dividend Will Be Reduced To €0.55
Stratec SE's ( ETR:SBS ) dividend is being reduced from last year's payment covering the same period to €0.55 on the...Analysartikel • Apr 01
Stratec SE Just Missed EPS By 24%: Here's What Analysts Think Will Happen Next
Shareholders might have noticed that Stratec SE ( ETR:SBS ) filed its yearly result this time last week. The early...Analysartikel • Mar 28
Stratec (ETR:SBS) Has Announced That Its Dividend Will Be Reduced To €0.55
The board of Stratec SE ( ETR:SBS ) has announced it will be reducing its dividend by 43% from last year's payment of...Analysartikel • Dec 21
Is There An Opportunity With Stratec SE's (ETR:SBS) 36% Undervaluation?
Key Insights Stratec's estimated fair value is €67.40 based on 2 Stage Free Cash Flow to Equity Stratec's €43.00 share...Analysartikel • Nov 03
Slowing Rates Of Return At Stratec (ETR:SBS) Leave Little Room For Excitement
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Analysartikel • Oct 19
We Think Stratec (ETR:SBS) Is Taking Some Risk With Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysartikel • Jul 12
Return Trends At Stratec (ETR:SBS) Aren't Appealing
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...Analysartikel • Jun 27
Stratec SE (ETR:SBS) Shares Could Be 43% Below Their Intrinsic Value Estimate
Key Insights Stratec's estimated fair value is €110 based on 2 Stage Free Cash Flow to Equity Stratec is estimated to...Analysartikel • May 25
Is Stratec (ETR:SBS) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Aktieägarnas avkastning
| SBS | DE Medical Equipment | DE Marknad | |
|---|---|---|---|
| 7D | 2.9% | 2.6% | 3.2% |
| 1Y | -34.6% | -27.3% | 2.5% |
Avkastning vs industri: SBS presterade sämre än German Medical Equipment branschen som gav -27.3 % under det senaste året.
Avkastning vs Marknaden: SBS presterade sämre än German marknaden som gav 2.5 % under det senaste året.
Prisvolatilitet
| SBS volatility | |
|---|---|
| SBS Average Weekly Movement | 6.1% |
| Medical Equipment Industry Average Movement | 6.1% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 13.6% |
| 10% least volatile stocks in DE Market | 2.7% |
Stabil aktiekurs: SBS har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för German.
Volatilitet över tid: SBS s veckovolatilitet ( 6% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1979 | 1,343 | Marcus Wolfinger | www.stratec.com |
Stratec SE, tillsammans med sina dotterbolag, utvecklar och tillverkar automations- och instrumentlösningar inom in vitro-diagnostik och biovetenskap i Tyskland, EU och internationellt. Företaget konstruerar och tillverkar automatiserade analyssystem för kunder inom klinisk diagnostik och bioteknik samt erbjuder komplexa förbrukningsvaror för diagnostik och medicinska tillämpningar. Företaget var tidigare känt som STRATEC Biomedical AG och bytte namn till Stratec SE i december 2018.
Stratec SE Sammanfattning av grunderna
| SBS grundläggande statistik | |
|---|---|
| Börsvärde | €209.57m |
| Vinst(TTM) | -€3.40m |
| Intäkter(TTM) | €243.93m |
0.9x
P/S-förhållande-61.6x
P/E-förhållandeÄr SBS övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| SBS resultaträkning (TTM) | |
|---|---|
| Intäkter | €243.93m |
| Kostnad för intäkter | €185.54m |
| Bruttovinst | €58.38m |
| Övriga kostnader | €61.78m |
| Intäkter | -€3.40m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
Aug 14, 2026
| Vinst per aktie (EPS) | -0.28 |
| Bruttomarginal | 23.93% |
| Nettovinstmarginal | -1.39% |
| Skuld/egenkapitalförhållande | 0% |
Hur har SBS utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
3.5%
Aktuell utdelningsavkastning-3,014%
UtbetalningskvotGer SBS en tillförlitlig utdelning?
Se SBS utdelningshistorik och jämförelsetal| Stratec datum för utdelning | |
|---|---|
| Ex utdelningsdag | Jun 24 2026 |
| Utbetalningsdag för utdelning | Jun 26 2026 |
| Dagar till Ex-utdelning | 31 days |
| Dagar till utdelningsdag | 33 days |
Ger SBS en tillförlitlig utdelning?
Se SBS utdelningshistorik och jämförelsetalFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/22 19:52 |
| Aktiekurs vid dagens slut | 2026/05/22 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Stratec SE bevakas av 11 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Michael Heider | Berenberg |
| Jan Koch | Deutsche Bank |
| Jan Koch | Deutsche Bank |